BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...increase neuroprotection, starting with a small molecule SARM1...
BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

...and Washington University School of Medicine scientists published in Cell Reports the identification of a small molecule SARM1...
...Institutes for BioMedical Research scientists detailed a similar concept in Cell Chemical Biology in December.TARGETSSARM1Sterile alpha and TIR motif containing 1 Danielle...
...Lilly and Co. Washington University School of Medicine in St. Louis Broad Institute of MIT and Harvard BioNTech SE NetScientific Sterile alpha and TIR motif containing 1 (SARM1) Autoimmune Multiple...
BioCentury | Oct 16, 2020
Deals

With Disarm deal, Atlas returns to Lilly to take neuro program forward

...Milbrandt and Aaron DiAntonio, who published a series of papers demonstrating that knocking out the SARM1...
...Atlas Venture, Lightstone Ventures and AbbVie Ventures, the biotech has developed a pipeline of preclinical SARM1...
...migraine prevention in 2018. TARGETSCGRP – calcitonin gene-related peptide SARM1sterile alpha and TIR motif containing 1 Virginia Li Disarm Therapeutics Inc. Eli Lilly and Co. SARM1...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

...veteran Alpna Seth, the South San Francisco company is developing a small molecule that inhibits SARM1...
...the University of Texas Southwestern Medical Center. Nura’s most advanced program, the as yet unnamed SARM1...
...Capital CEO: Alpna Seth Patents: Undisclosed Targets SARM1 - Sterile alpha and TIR motif containing 1 Elizabeth S. Eaton, Staff Writer Nura Bio Inc. Sterile alpha and TIR motif containing 1 (SARM1) Alpna...
BioCentury | Mar 14, 2019
Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
BioCentury | Dec 6, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

...the central and peripheral nervous systems caused by sterile α and TIR motif containing 1 (SARM1...
BioCentury | Nov 30, 2018
Clinical News

Disarm validates biomarkers for SARM1 inhibition

...Mass.), which is developing small molecule inhibitors of sterile α and TIR motif containing 1 (SARM1...
...axonal degeneration in a range of neurological disorders, said it validated two biomarkers that measure SARM1...
...SARM1 inhibitors Business: Neurology Indication: Treat neurological disorders Mark Zipkin Disarm Therapeutics Inc. Cyclic ADP-ribose (cADPR) Neurofilament light (NEFL) (NF-L) Sterile alpha and TIR motif containing 1 (SARM1)...
BioCentury | Oct 19, 2018
Clinical News

Viking's VK5211 meets primary in Phase II for acute hip fracture

Viking Therapeutics Inc. (NASDAQ:VKTX) said VK5211 met the primary endpoint of increasing lean body mass from baseline to week 12 vs. placebo in a Phase II trial in patients recovering from acute hip fracture surgery....
BioCentury | Sep 28, 2018
Clinical News

GTx's enobosarm fails Phase II for stress urinary incontinence

GTx Inc. (NASDAQ:GTXI) said it enobosarm (GTx-024) failed in the Phase II ASTRID trial to treat stress urinary incontinence. Among the 493 postmenopausal women enrolled in the double-blind, U.S. trial, neither of two doses of...
BioCentury | Sep 21, 2018
Clinical News

GTx shares crater after incontinence readout

GTx Inc. (NASDAQ:GTXI) shed 92% of its value Friday, falling from the small cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024) failed in the Phase II ASTRID...
Items per page:
1 - 10 of 147